Online first
Editorial
Published online: 2025-03-17
MicroRNAs unlock the mystery of arrhythmogenic cardiomyopathy
Pubmed: 40111241
Abstract
Not available
References
- Hoorntje ET, Te Rijdt WP, James CA, et al. Arrhythmogenic cardiomyopathy: Pathology, genetics, and concepts in pathogenesis. Cardiovasc Res. 2017; 113(12): 1521–1531.
- Corrado D, Anastasakis A, Basso C, et al. Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. Int J Cardiol. 2024; 395: 131447.
- Ho PTB, Clark IM, Le LTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. 2022; 23(13): 7167.
- Liang LW, Hasegawa K, Maurer MS, et al. Comprehensive transcriptomics profiling of microRNA reveals plasma circulating biomarkers of hypertrophic cardiomyopathy and dysregulated signaling pathways. Circ Heart Fail. 2023; 16(6): e010010.
- Vegter EL, van der Meer P, de Windt LJ, et al. MicroRNAs in heart failure: From biomarker to target for therapy. Eur J Heart Fail. 2016; 18(5): 457–468.
- Kuch A, Procyk G, Borowiec K, et al. The role of MicroRNAs in arrhythmogenic right ventricular cardiomyopathy: A systematic review. Kardiol Pol. 2025 [Epub ahead of print].
